Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AEON Biopharma, Inc.PMGM · Entity 7859 | Director | February 08, 2021 | February 09, 2021 |
| Orthofix Medical Inc.OFIX · Entity 1975 | CFO | March 04, 2026 | March 06, 2026 |
| RxSight, Inc.RXST · Entity 1226 | Director | June 17, 2026 | June 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AEON Biopharma, Inc.
Report date February 08, 2021 · Filed February 09, 2021
This filing explicitly reported no securities owned.
Orthofix Medical Inc.
Report date March 04, 2026 · Filed March 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 88,746 |
Last balance in matching sequence
After 2026-03-05 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-03-04 · Sale · Disposed 2,425 · Balance 91,109 F1: Represents the number of shares of common stock sold to satisfy tax withholding obligations in connection with the settlement of restricted stock units, pursuant to a pre-existing sell-to-cover requirement previously approved and mandated by the Compensation and Talent Development Committee of the Company's Board of Directors (the administrator of the plan pursuant to which such restricted stock units were granted). Such sale was made without the exercise of any discretion by the reporting person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.80 to $13.03, inclusive. The reporting person undertakes to provide to Orthofix Medical Inc., any security holder of Orthofix Medical Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4) to this Form 4. F3: Includes 69,552 previously reported restricted stock units. Row 2 · 2026-03-05 · Sale · Disposed 2,363 · Balance 88,746 F1: Represents the number of shares of common stock sold to satisfy tax withholding obligations in connection with the settlement of restricted stock units, pursuant to a pre-existing sell-to-cover requirement previously approved and mandated by the Compensation and Talent Development Committee of the Company's Board of Directors (the administrator of the plan pursuant to which such restricted stock units were granted). Such sale was made without the exercise of any discretion by the reporting person. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.48 to $12.72, inclusive. F3: Includes 69,552 previously reported restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of common stock sold to satisfy tax withholding obligations in connection with the settlement of restricted stock units, pursuant to a pre-existing sell-to-cover requirement previously approved and mandated by the Compensation and Talent Development Committee of the Company's Board of Directors (the administrator of the plan pursuant to which such restricted stock units were granted). Such sale was made without the exercise of any discretion by the reporting person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.80 to $13.03, inclusive. The reporting person undertakes to provide to Orthofix Medical Inc., any security holder of Orthofix Medical Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4) to this Form 4.
F3: Includes 69,552 previously reported restricted stock units.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.48 to $12.72, inclusive.
RxSight, Inc.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 78,076 |
Reported balance
After 2026-06-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 37,037 · Balance 78,076 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. F2: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the date of the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 17, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock.
F2: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the date of the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 17, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Wright Medical Group N.V.
Report date November 11, 2020 · Filed November 13, 2020
Section 16 reporting ended · disclosed 2020-11-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, par value EUR 0.03 per shareSEC Table I · non-derivative | Direct | 18,256 |
Reported balance
After 2020-11-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-11-11 · Other · Disposed 31,782 · Balance 18,256 F1: On November 4, 2019, Wright Medical Group N.V. (the "Issuer") entered into a purchase agreement (the "Purchase Agreement") with Stryker Corporation and its subsidiary, Stryker B.V. (the "Purchaser"). Pursuant to the terms of the Purchase Agreement, the Purchaser commenced a tender offer for all the outstanding ordinary shares, par value EUR 0.03 per share ("Shares"), of the Issuer (the "Offer"), and, on November 11, 2020 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time, including 31,782 Shares tendered by the reporting person, in exchange for a cash payment equal to $30.75 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as promptly as practicable following the Closing (as defined in the Purchase Agreement). F2: Includes 5,849 Shares issuable upon vesting of restricted stock units in respect of Shares (collectively, "Wright RSUs") and 12,407 Shares issuable upon vesting of Wright RSUs granted on July 23, 2020 (the "2020 RSUs"). See note (5) below for the treatment of such Wright RSUs and Wright 2020 RSUs in connection with the Offer. |
| Ordinary Shares, par value EUR 0.03 per shareSEC Table I · non-derivative | Direct | 6,801 |
Reported balance
After 2020-11-11 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2020-11-11 · Disposition to issuer · Disposed 11,455 · Balance 6,801 F3: Represents Shares issuable upon vesting of the 2020 RSUs which did not vest at the Acceptance Time and were cancelled and forfeited at the Closing for no Offer Consideration or other consideration. See note (5) below for the treatment of the Wright 2020 RSUs in connection with the Offer. F4: Includes 5,849 Shares issuable upon vesting of the Wright RSUs and 952 Shares issuable upon vesting of the 2020 RSUs. See Note (5) below for the treatment of Wright RSUs and Wright 2020 RSUs in connection with the Offer. |
| Ordinary Shares, par value EUR 0.03 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2020-11-11 · Disposition to issuer · Disposed 6,801 · Balance 0 F5: See Exhibit 99.1. |
| Ordinary Shares, par value EUR 0.03 per shareSEC Table I · non-derivative | Direct | 15,842 |
Reported balance
After 2020-11-11 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2020-11-11 · Grant · Acquired 15,842 · Balance 15,842 F6: In connection with the Offer, each performance share unit in respect of Shares (a "Wright PSU") that was outstanding and unvested immediately prior to the Acceptance Time vested in full at the Acceptance Time, and, at the Closing, was cancelled in exchange for a cash payment equal to the product of (a) $30.75 multiplied by (b) the total number of Shares subject to such Wright PSU as of immediately prior to the Acceptance Time determined based on the maximum achievement of the applicable performance condition, without interest and less applicable withholding taxes. |
| Ordinary Shares, par value EUR 0.03 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2020-11-11 · Disposition to issuer · Disposed 15,842 · Balance 0 F6: In connection with the Offer, each performance share unit in respect of Shares (a "Wright PSU") that was outstanding and unvested immediately prior to the Acceptance Time vested in full at the Acceptance Time, and, at the Closing, was cancelled in exchange for a cash payment equal to the product of (a) $30.75 multiplied by (b) the total number of Shares subject to such Wright PSU as of immediately prior to the Acceptance Time determined based on the maximum achievement of the applicable performance condition, without interest and less applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.84 · Expires 2029-07-26 | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-11-11 · Disposition to issuer · Disposed 12,152 · Balance 0 F7: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.49 · Expires 2028-07-24 | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-11-11 · Disposition to issuer · Disposed 10,651 · Balance 0 F7: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.86 · Expires 2027-07-25 | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-11-11 · Disposition to issuer · Disposed 10,622 · Balance 0 F7: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.24 · Expires 2026-07-19 | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-11-11 · Disposition to issuer · Disposed 15,720 · Balance 0 F7: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.62 · Expires 2025-10-13 | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-11-11 · Disposition to issuer · Disposed 14,293 · Balance 0 F7: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.62 · Expires 2025-10-13 | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2020-11-11 · Disposition to issuer · Disposed 14,293 · Balance 0 F7: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.06 · Expires 2024-05-13 | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2020-11-11 · Disposition to issuer · Disposed 8,546 · Balance 0 F7: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.93 · Expires 2023-05-14 | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2020-11-11 · Disposition to issuer · Disposed 13,816 · Balance 0 F7: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.36 · Expires 2022-05-18 | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2020-11-11 · Disposition to issuer · Disposed 11,618 · Balance 0 F7: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: On November 4, 2019, Wright Medical Group N.V. (the "Issuer") entered into a purchase agreement (the "Purchase Agreement") with Stryker Corporation and its subsidiary, Stryker B.V. (the "Purchaser"). Pursuant to the terms of the Purchase Agreement, the Purchaser commenced a tender offer for all the outstanding ordinary shares, par value EUR 0.03 per share ("Shares"), of the Issuer (the "Offer"), and, on November 11, 2020 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time, including 31,782 Shares tendered by the reporting person, in exchange for a cash payment equal to $30.75 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as promptly as practicable following the Closing (as defined in the Purchase Agreement).
F2: Includes 5,849 Shares issuable upon vesting of restricted stock units in respect of Shares (collectively, "Wright RSUs") and 12,407 Shares issuable upon vesting of Wright RSUs granted on July 23, 2020 (the "2020 RSUs"). See note (5) below for the treatment of such Wright RSUs and Wright 2020 RSUs in connection with the Offer.
F3: Represents Shares issuable upon vesting of the 2020 RSUs which did not vest at the Acceptance Time and were cancelled and forfeited at the Closing for no Offer Consideration or other consideration. See note (5) below for the treatment of the Wright 2020 RSUs in connection with the Offer.
F4: Includes 5,849 Shares issuable upon vesting of the Wright RSUs and 952 Shares issuable upon vesting of the 2020 RSUs. See Note (5) below for the treatment of Wright RSUs and Wright 2020 RSUs in connection with the Offer.
F5: See Exhibit 99.1.
F6: In connection with the Offer, each performance share unit in respect of Shares (a "Wright PSU") that was outstanding and unvested immediately prior to the Acceptance Time vested in full at the Acceptance Time, and, at the Closing, was cancelled in exchange for a cash payment equal to the product of (a) $30.75 multiplied by (b) the total number of Shares subject to such Wright PSU as of immediately prior to the Acceptance Time determined based on the maximum achievement of the applicable performance condition, without interest and less applicable withholding taxes.
F7: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 18, 2026 20:06 UTC | RxSight, Inc. RXST · Entity 1226 | GrantCommon Stock | 37,037 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-275819 · ownership.xml · nonDerivative · entry 1 Andrews Julie · CIK 0001550508 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,076 F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. F2 · shares: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the date of the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 17, 2026. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. Read SEC document |
| March 05, 2026 Filed Mar 6, 2026 21:20 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | SaleCommon Stock | 2,363 | $12.55 | $29,657.54 |
DisclosureSEC source: 0001193125-26-096594 · ownership.xml · nonDerivative · entry 2 Andrews Julie · CIK 0001550508 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,746 F1 · kind: Represents the number of shares of common stock sold to satisfy tax withholding obligations in connection with the settlement of restricted stock units, pursuant to a pre-existing sell-to-cover requirement previously approved and mandated by the Compensation and Talent Development Committee of the Company's Board of Directors (the administrator of the plan pursuant to which such restricted stock units were granted). Such sale was made without the exercise of any discretion by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.48 to $12.72, inclusive. F3 · balance_after: Includes 69,552 previously reported restricted stock units. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:20 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | SaleCommon Stock | 2,425 | $12.92 | $31,322.03 |
DisclosureSEC source: 0001193125-26-096594 · ownership.xml · nonDerivative · entry 1 Andrews Julie · CIK 0001550508 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,109 F1 · kind: Represents the number of shares of common stock sold to satisfy tax withholding obligations in connection with the settlement of restricted stock units, pursuant to a pre-existing sell-to-cover requirement previously approved and mandated by the Compensation and Talent Development Committee of the Company's Board of Directors (the administrator of the plan pursuant to which such restricted stock units were granted). Such sale was made without the exercise of any discretion by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.80 to $13.03, inclusive. The reporting person undertakes to provide to Orthofix Medical Inc., any security holder of Orthofix Medical Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4) to this Form 4. F3 · balance_after: Includes 69,552 previously reported restricted stock units. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:50 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | GrantEmployee Stock Option (Right to Buy) · Derivative | 84,261 | $0.00 Strike: $13.03 | $0.00 |
DisclosureSEC source: 0001193125-26-094472 · ownership.xml · derivative · entry 2 Andrews Julie · CIK 0001550508 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,261 Underlying: Common Stock · 84,261 shares Expires 2033-03-03 F3 · derivative.exercise_date: The options vest and become exercisable with respect to one-third (1/3rd) of the shares covered thereby on the first, second and third anniversary of the Grant Date. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:50 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | GrantCommon Stock | 35,495 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-094472 · ownership.xml · nonDerivative · entry 1 Andrews Julie · CIK 0001550508 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,534 F1 · shares: Represents a grant of restricted stock units approved by the Compensation and Talent Development Committee of the Company's Board of Directors (the administrator of the plan pursuant to which such restricted stock units were granted). The restricted stock units vest with respect to one-third (1/3rd) of the shares of stock covered thereby on the first, second and third anniversary of the Grant Date. F2 · balance_after: Includes 45,590 previously reported restricted stock units. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 21:09 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | SaleCommon Stock | 4,873 | $14.38 | $70,073.74 |
DisclosureSEC source: 0001193125-26-017960 · ownership.xml · nonDerivative · entry 1 Andrews Julie · CIK 0001550508 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,039 F1 · kind: Represents the number of shares of common stock sold to satisfy tax withholding obligations in connection with the settlement of restricted stock units, pursuant to a pre-existing sell-to-cover requirement previously approved and mandated by the Compensation and Talent Development Committee of the Company's Board of Directors (the administrator of the plan pursuant to which such restricted stock units were granted). Such sale was made without the exercise of any discretion by the reporting person. F2 · balance_after: Includes 45,590 previously reported restricted stock units. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 01:34 UTC | RxSight, Inc. RXST · Entity 1226 | GrantCommon Stock | 10,752 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-081956 · ownership.xml · nonDerivative · entry 1 Andrews Julie · CIK 0001550508 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,039 F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. F2 · shares: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the date immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 3, 2025. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:16 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | GrantEmployee Stock Option (Right to Buy) · Derivative | 82,070 | $0.00 Strike: $16.98 | $0.00 |
DisclosureSEC source: 0000950170-25-033602 · ownership.xml · derivative · entry 2 Andrews Julie · CIK 0001550508 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,070 Underlying: Common Stock · 82,070 shares Expires 2032-03-03 F3 · derivative.exercise_date: The options vest and become exercisable with respect to one-third (1/3rd) of the shares covered thereby on the first, second and third anniversary of the Grant Date. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:16 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | GrantCommon Stock | 34,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-033602 · ownership.xml · nonDerivative · entry 1 Andrews Julie · CIK 0001550508 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,912 F1 · shares: The restricted stock units vest with respect to one-third (1/3rd) of the shares of stock covered hereby on each of the first, second and third anniversaries of the Grant Date. F2 · balance_after: Includes 21,979 previously reported restricted stock units. Read SEC document |
| January 16, 2025 Filed Jan 21, 2025 21:18 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | SaleCommon Stock | 4,655 | $17.89 | $83,277.95 |
DisclosureSEC source: 0000950170-25-007228 · ownership.xml · nonDerivative · entry 1 Andrews Julie · CIK 0001550508 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,312 F1 · kind: Represents the number of shares of common stock sold to satisfy tax withholding obligations in connection with the settlement of restricted stock units, pursuant to a pre-existing sell-to-cover requirement previously approved and mandated by the Compensation and Talent Development Committee of the Company's Board of Directors (the administrator of the plan pursuant to which such restricted stock units were granted). Such sale was made without the exercise of any discretion by the reporting person. F2 · balance_after: Includes 21,979 previously reported restricted stock units. Read SEC document |
| June 14, 2024 Filed Jun 17, 2024 22:45 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 3,685 | $58.53 | $215,679.73 |
DisclosureSEC source: 0000950170-24-074473 · ownership.xml · nonDerivative · entry 2 Andrews Julie · CIK 0001550508 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,287 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2024 by the Reporting Person. F3 · price: Represents the weighted average share price of an aggregate total of 3,685 shares sold in the price range of $58.32 to $59.03 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 14, 2024 Filed Jun 17, 2024 22:45 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 11,940 | $57.84 | $690,608.41 |
DisclosureSEC source: 0000950170-24-074473 · ownership.xml · nonDerivative · entry 1 Andrews Julie · CIK 0001550508 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,972 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2024 by the Reporting Person. F2 · price: Represents the weighted average share price of an aggregate total of 11,940 shares sold in the price range of $57.32 to $58.29 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 20:05 UTC | RxSight, Inc. RXST · Entity 1226 | GrantCommon Stock | 2,554 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-071281 · ownership.xml · nonDerivative · entry 1 Andrews Julie · CIK 0001550508 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,912 F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. F2 · shares: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the earlier of the (i) the one (1) year anniversary of the Date of Grant or (ii) the date immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 6, 2024. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. Read SEC document |
| January 15, 2024 Filed Jan 18, 2024 00:22 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | GrantEmployee Stock Option (right to buy) · Derivative | 76,878 | $0.00 Strike: $13.65 | $0.00 |
DisclosureSEC source: 0001209191-24-001811 · doc4.xml · derivative · entry 2 Andrews Julie · CIK 0001550508 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,878 Underlying: Common Stock · 76,878 shares Expires 2031-01-15 F2 · derivative.exercise_date: The options vest and become exercisable with respect to one-third (1/3rd) of the shares covered thereby on the first anniversary of the Grant Date and one-twelfth (1/12th) of the shares covered thereby on each of the 15-month, 18-month, 21-month, 24-month, 27-month, 30-month, 33-month and 36-month anniversaries of the Grant Date. Read SEC document |
| January 15, 2024 Filed Jan 18, 2024 00:22 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | GrantCommon Stock | 32,967 | $13.65 | $449,999.55 |
DisclosureSEC source: 0001209191-24-001811 · doc4.xml · nonDerivative · entry 1 Andrews Julie · CIK 0001550508 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,967 F1 · shares: The restricted stock units vest with respect to one-third (1/3rd) of the shares of stock covered hereby on each of the first, second and third anniversaries of the Grant Date. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 20:27 UTC | RxSight, Inc. RXST · Entity 1226 | GrantCommon Stock | 5,731 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-034296 · doc4.xml · nonDerivative · entry 1 Andrews Julie · CIK 0001550508 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,358 F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. F2 · shares: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the earlier of the (i) the one (1) year anniversary of the Date of Grant or (ii) the date immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 1, 2023. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. Read SEC document |
| June 02, 2022 Filed Jun 4, 2022 00:19 UTC | RxSight, Inc. RXST · Entity 1226 | GrantCommon Stock | 8,624 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-034386 · doc4.xml · nonDerivative · entry 1 Andrews Julie · CIK 0001550508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,627 F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. F2 · shares: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the earlier of the (i) the one (1) year anniversary of the Date of Grant or (ii) the date immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 2, 2022. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 23:18 UTC | RxSight, Inc. RXST · Entity 1226 | PurchaseCommon Stock | 15,625 | $16.00 | $250,000.00 |
DisclosureSEC source: 0000899243-21-031812 · doc4.xml · nonDerivative · entry 3 Andrews Julie · CIK 0001550508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,003 Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 23:18 UTC | RxSight, Inc. RXST · Entity 1226 | GrantCommon Stock | 7,645 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-031812 · doc4.xml · nonDerivative · entry 2 Andrews Julie · CIK 0001550508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,378 F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. F3 · shares: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one third of the RSUs subject to the award shall vest on each annual anniversary of August 3, 2021. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 23:18 UTC | RxSight, Inc. RXST · Entity 1226 | GrantCommon Stock | 5,733 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-031812 · doc4.xml · nonDerivative · entry 1 Andrews Julie · CIK 0001550508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,733 F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. F2 · shares: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the date immediately prior to the first annual meeting of stockholders following August 3, 2021. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 18:04 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | Disposition to issuerStock Option (right to buy) · Derivative | 11,618 | Not disclosed Strike: $19.36 | Not disclosed |
DisclosureSEC source: 0001790300-20-000007 · primary_doc.xml · derivative · entry 14 Andrews Julie · CIK 0001550508 · SVP, Global Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 11,618 shares Expires 2022-05-18 F7 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F7 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 18:04 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | Disposition to issuerStock Option (right to buy) · Derivative | 13,816 | Not disclosed Strike: $23.93 | Not disclosed |
DisclosureSEC source: 0001790300-20-000007 · primary_doc.xml · derivative · entry 13 Andrews Julie · CIK 0001550508 · SVP, Global Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 13,816 shares Expires 2023-05-14 F7 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F7 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 18:04 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | Disposition to issuerStock Option (right to buy) · Derivative | 8,546 | Not disclosed Strike: $29.06 | Not disclosed |
DisclosureSEC source: 0001790300-20-000007 · primary_doc.xml · derivative · entry 12 Andrews Julie · CIK 0001550508 · SVP, Global Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 8,546 shares Expires 2024-05-13 F7 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F7 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 18:04 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | Disposition to issuerStock Option (right to buy) · Derivative | 14,293 | Not disclosed Strike: $20.62 | Not disclosed |
DisclosureSEC source: 0001790300-20-000007 · primary_doc.xml · derivative · entry 11 Andrews Julie · CIK 0001550508 · SVP, Global Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 14,293 shares Expires 2025-10-13 F7 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F7 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 18:04 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | Disposition to issuerStock Option (right to buy) · Derivative | 14,293 | Not disclosed Strike: $20.62 | Not disclosed |
DisclosureSEC source: 0001790300-20-000007 · primary_doc.xml · derivative · entry 10 Andrews Julie · CIK 0001550508 · SVP, Global Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 14,293 shares Expires 2025-10-13 F7 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F7 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 18:04 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | Disposition to issuerStock Option (right to buy) · Derivative | 15,720 | Not disclosed Strike: $21.24 | Not disclosed |
DisclosureSEC source: 0001790300-20-000007 · primary_doc.xml · derivative · entry 9 Andrews Julie · CIK 0001550508 · SVP, Global Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 15,720 shares Expires 2026-07-19 F7 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F7 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 18:04 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | Disposition to issuerStock Option (right to buy) · Derivative | 10,622 | Not disclosed Strike: $27.86 | Not disclosed |
DisclosureSEC source: 0001790300-20-000007 · primary_doc.xml · derivative · entry 8 Andrews Julie · CIK 0001550508 · SVP, Global Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 10,622 shares Expires 2027-07-25 F7 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F7 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 18:04 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | Disposition to issuerStock Option (right to buy) · Derivative | 10,651 | Not disclosed Strike: $24.49 | Not disclosed |
DisclosureSEC source: 0001790300-20-000007 · primary_doc.xml · derivative · entry 7 Andrews Julie · CIK 0001550508 · SVP, Global Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 10,651 shares Expires 2028-07-24 F7 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F7 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 18:04 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | Disposition to issuerStock Option (right to buy) · Derivative | 12,152 | Not disclosed Strike: $27.84 | Not disclosed |
DisclosureSEC source: 0001790300-20-000007 · primary_doc.xml · derivative · entry 6 Andrews Julie · CIK 0001550508 · SVP, Global Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 12,152 shares Expires 2029-07-26 F7 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F7 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 18:04 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | Disposition to issuerOrdinary Shares, par value EUR 0.03 per share | 15,842 | $30.75 | $487,141.50 |
DisclosureSEC source: 0001790300-20-000007 · primary_doc.xml · nonDerivative · entry 5 Andrews Julie · CIK 0001550508 · SVP, Global Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F6 · kind: In connection with the Offer, each performance share unit in respect of Shares (a "Wright PSU") that was outstanding and unvested immediately prior to the Acceptance Time vested in full at the Acceptance Time, and, at the Closing, was cancelled in exchange for a cash payment equal to the product of (a) $30.75 multiplied by (b) the total number of Shares subject to such Wright PSU as of immediately prior to the Acceptance Time determined based on the maximum achievement of the applicable performance condition, without interest and less applicable withholding taxes. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 18:04 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | GrantOrdinary Shares, par value EUR 0.03 per share | 15,842 | $0.00 | $0.00 |
DisclosureSEC source: 0001790300-20-000007 · primary_doc.xml · nonDerivative · entry 4 Andrews Julie · CIK 0001550508 · SVP, Global Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,842 F6 · kind: In connection with the Offer, each performance share unit in respect of Shares (a "Wright PSU") that was outstanding and unvested immediately prior to the Acceptance Time vested in full at the Acceptance Time, and, at the Closing, was cancelled in exchange for a cash payment equal to the product of (a) $30.75 multiplied by (b) the total number of Shares subject to such Wright PSU as of immediately prior to the Acceptance Time determined based on the maximum achievement of the applicable performance condition, without interest and less applicable withholding taxes. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 18:04 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | Disposition to issuerOrdinary Shares, par value EUR 0.03 per share | 6,801 | $30.75 | $209,130.75 |
DisclosureSEC source: 0001790300-20-000007 · primary_doc.xml · nonDerivative · entry 3 Andrews Julie · CIK 0001550508 · SVP, Global Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F5 · kind: See Exhibit 99.1. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 18:04 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | Disposition to issuerOrdinary Shares, par value EUR 0.03 per share | 11,455 | $0.00 | $0.00 |
DisclosureSEC source: 0001790300-20-000007 · primary_doc.xml · nonDerivative · entry 2 Andrews Julie · CIK 0001550508 · SVP, Global Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,801 F3 · shares: Represents Shares issuable upon vesting of the 2020 RSUs which did not vest at the Acceptance Time and were cancelled and forfeited at the Closing for no Offer Consideration or other consideration. See note (5) below for the treatment of the Wright 2020 RSUs in connection with the Offer. F4 · balance_after: Includes 5,849 Shares issuable upon vesting of the Wright RSUs and 952 Shares issuable upon vesting of the 2020 RSUs. See Note (5) below for the treatment of Wright RSUs and Wright 2020 RSUs in connection with the Offer. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 18:04 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | OtherOrdinary Shares, par value EUR 0.03 per share | 31,782 | $30.75 | $977,296.50 |
DisclosureSEC source: 0001790300-20-000007 · primary_doc.xml · nonDerivative · entry 1 Andrews Julie · CIK 0001550508 · SVP, Global Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,256 F1 · kind: On November 4, 2019, Wright Medical Group N.V. (the "Issuer") entered into a purchase agreement (the "Purchase Agreement") with Stryker Corporation and its subsidiary, Stryker B.V. (the "Purchaser"). Pursuant to the terms of the Purchase Agreement, the Purchaser commenced a tender offer for all the outstanding ordinary shares, par value EUR 0.03 per share ("Shares"), of the Issuer (the "Offer"), and, on November 11, 2020 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time, including 31,782 Shares tendered by the reporting person, in exchange for a cash payment equal to $30.75 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as promptly as practicable following the Closing (as defined in the Purchase Agreement). F2 · balance_after: Includes 5,849 Shares issuable upon vesting of restricted stock units in respect of Shares (collectively, "Wright RSUs") and 12,407 Shares issuable upon vesting of Wright RSUs granted on July 23, 2020 (the "2020 RSUs"). See note (5) below for the treatment of such Wright RSUs and Wright 2020 RSUs in connection with the Offer. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 16:10 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | SaleOrdinary Shares, par value EUR 0.03 per share | 1,083 | $30.18 | $32,681.15 |
DisclosureSEC source: 0001235802-20-000101 · primary_doc.xml · nonDerivative · entry 1 Andrews Julie · CIK 0001550508 · SVP, Global Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,038 F1 · kind: These shares were sold under a pre-arranged sales instruction pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, to cover the estimated tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.17 to $30.18, inclusive. The reporting person undertakes to provide to Wright Medical Group N.V., any security holder of Wright Medical Group N.V., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F3 · balance_after: Includes 2,885 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan and 15,371 shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2017 Equity and Incentive Plan. Read SEC document |
| July 23, 2020 Filed Jul 27, 2020 16:01 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | GrantOrdinary Shares, par value EUR 0.03 per share | 12,407 | $0.00 | $0.00 |
DisclosureSEC source: 0001235802-20-000080 · primary_doc.xml · nonDerivative · entry 1 Andrews Julie · CIK 0001550508 · SVP, Global Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,121 F1 · shares: These ordinary shares will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2017 Equity and Incentive Plan. The grant agreement contemplates that the shares will vest pro rata through the closing of the previously announced Stryker transaction, and shares unvested at closing will be cancelled. F2 · balance_after: Includes 4,777 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan and 16,358 shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2017 Equity and Incentive Plan. Read SEC document |
| June 30, 2020 Filed Jul 1, 2020 18:18 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | SaleOrdinary Shares, par value EUR 0.03 per share | 2,691 | $29.53 | $79,473.30 |
DisclosureSEC source: 0001686266-20-000004 · primary_doc.xml · nonDerivative · entry 2 Andrews Julie · CIK 0001550508 · SVP, Global Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,714 F3 · kind: These shares were sold under a pre-arranged sales instruction pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, to cover the estimated tax withholding obligations in connection with the vesting of performance share unit awards. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.5308 to $29.535, inclusive. The reporting person undertakes to provide to Wright Medical Group N.V., any security holder of Wright Medical Group N.V., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F2 · balance_after: Includes 4,777 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan and 3,951 shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2017 Equity and Incentive Plan. Read SEC document |
| June 29, 2020 Filed Jul 1, 2020 18:18 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | GrantOrdinary Shares, par value EUR 0.03 per share | 7,196 | $0.00 | $0.00 |
DisclosureSEC source: 0001686266-20-000004 · primary_doc.xml · nonDerivative · entry 1 Andrews Julie · CIK 0001550508 · SVP, Global Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,405 F1 · shares: Represents the payout of a performance share unit award for the June 26, 2017 to June 28, 2020 performance period under the Wright Medical Group N.V. 2017 Equity and Incentive Plan, as approved by the Issuer's Compensation Committee of its Board of Directors. Performance share unit awards are paid in ordinary shares of the Issuer. F2 · balance_after: Includes 4,777 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan and 3,951 shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2017 Equity and Incentive Plan. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 16:08 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | SaleOrdinary Shares, par value EUR 0.03 per share | 505 | $29.68 | $14,988.96 |
DisclosureSEC source: 0001235802-20-000056 · primary_doc.xml · nonDerivative · entry 1 Andrews Julie · CIK 0001550508 · SVP, Global Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,209 F1 · kind: These shares were sold under a pre-arranged sales instruction pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, to cover the estimated tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.6701 to $29.6850, inclusive. The reporting person undertakes to provide to Wright Medical Group N.V., any security holder of Wright Medical Group N.V., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F3 · balance_after: Includes 4,777 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan and 3,951 shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2017 Equity and Incentive Plan. Read SEC document |
| December 20, 2019 Filed Dec 23, 2019 16:16 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | Exercise / conversionStock Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $19.36 | $0.00 |
DisclosureSEC source: 0001235802-19-000141 · primary_doc.xml · derivative · entry 3 Andrews Julie · CIK 0001550508 · SVP, Global Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,618 Underlying: Ordinary Shares · 9,000 shares Expires 2022-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise and sale of vested stock options in connection with 280G tax planning under a pre-arranged sales instruction pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · derivative.exercise_date: This option has fully vested. Read SEC document |
| December 20, 2019 Filed Dec 23, 2019 16:16 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | SaleOrdinary Shares, par value EUR 0.03 per share | 7,001 | $30.10 | $210,711.90 |
DisclosureSEC source: 0001235802-19-000141 · primary_doc.xml · nonDerivative · entry 2 Andrews Julie · CIK 0001550508 · SVP, Global Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,714 F1 · kind: Exercise and sale of vested stock options in connection with 280G tax planning under a pre-arranged sales instruction pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.08 to $30.125, inclusive. The reporting person undertakes to provide to Wright Medical Group N.V., any security holder of Wright Medical Group N.V., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F2 · balance_after: Includes 1,368 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2010 Incentive Plan. 4,777 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan and 3,951 shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2017 Equity and Incentive Plan. Read SEC document |
| December 20, 2019 Filed Dec 23, 2019 16:16 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | Exercise / conversionOrdinary Shares, par value EUR 0.03 per share | 9,000 | $19.36 | $174,240.00 |
DisclosureSEC source: 0001235802-19-000141 · primary_doc.xml · nonDerivative · entry 1 Andrews Julie · CIK 0001550508 · SVP, Global Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,715 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise and sale of vested stock options in connection with 280G tax planning under a pre-arranged sales instruction pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes 1,368 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2010 Incentive Plan. 4,777 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan and 3,951 shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2017 Equity and Incentive Plan. Read SEC document |
| August 16, 2019 Filed Aug 20, 2019 16:08 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | SaleOrdinary Shares, par value EUR 0.03 per share | 712 | $21.03 | $14,973.43 |
DisclosureSEC source: 0001235802-19-000109 · primary_doc.xml · nonDerivative · entry 1 Andrews Julie · CIK 0001550508 · VP, Finance, CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,715 F1 · kind: These shares were sold under a pre-arranged sales instruction pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, to cover the estimated tax withholding obligations in connection with the vesting of restricted stock units. F2 · balance_after: Includes 1,368 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2010 Incentive Plan. 4,777 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan and 3,951 shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2017 Equity and Incentive Plan. Read SEC document |
| July 26, 2019 Filed Jul 30, 2019 16:06 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | GrantStock Option (right to buy) · Derivative | 12,152 | $0.00 Strike: $27.84 | $0.00 |
DisclosureSEC source: 0001235802-19-000074 · primary_doc.xml · derivative · entry 2 Andrews Julie · CIK 0001550508 · VP, Finance, CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,152 Underlying: Ordinary Shares · 12,152 shares Expires 2029-07-26 F3 · derivative.exercise_date: This option vests with respect to 25% of the shares on July 26, 2020 and with respect to the remaining 75% of such shares over the three-year period thereafter in 36 as nearly equal as possible monthly installments. Read SEC document |
| July 26, 2019 Filed Jul 30, 2019 16:06 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | GrantOrdinary Shares, par value EUR 0.03 per share | 3,951 | $0.00 | $0.00 |
DisclosureSEC source: 0001235802-19-000074 · primary_doc.xml · nonDerivative · entry 1 Andrews Julie · CIK 0001550508 · VP, Finance, CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,427 F1 · shares: These ordinary shares will be issued over time upon vesting pursuant to a restricted stock unit granted under the Wright Medical Group N.V. Amended and Restated 2017 Equity and Incentive Plan. F2 · balance_after: Includes 1,368 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2010 Incentive Plan. 6,669 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan and 3,951 shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2017 Equity and Incentive Plan. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 16:11 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | SaleOrdinary Shares, par value EUR 0.03 per share | 1,447 | $30.65 | $44,346.21 |
DisclosureSEC source: 0001235802-19-000047 · primary_doc.xml · nonDerivative · entry 1 Andrews Julie · CIK 0001550508 · VP, Finance and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,476 F1 · kind: These shares were sold under a pre-arranged sales instruction pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, to cover the estimated tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.62 to $30.65, inclusive. The reporting person undertakes to provide to Wright Medical Group N.V., any security holder of Wright Medical Group N.V., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F3 · balance_after: Includes 1,368 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2010 Incentive Plan and 6,669 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan. Read SEC document |
| August 16, 2018 Filed Aug 20, 2018 16:15 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | SaleOrdinary Shares, par value EUR 0.03 per share | 348 | $27.14 | $9,446.15 |
DisclosureSEC source: 0001235802-18-000126 · primary_doc.xml · nonDerivative · entry 1 Andrews Julie · CIK 0001550508 · VP, Finance and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,923 F1 · kind: These shares were sold under a pre-arranged sales instruction pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, to cover the estimated tax withholding obligations in connection with the vesting of restricted stock units. F2 · balance_after: Includes 5,205 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2010 Incentive Plan and 6,669 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan. Read SEC document |
| July 24, 2018 Filed Jul 26, 2018 16:06 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | GrantStock Option (right to buy) · Derivative | 10,651 | $0.00 Strike: $24.49 | $0.00 |
DisclosureSEC source: 0001235802-18-000099 · primary_doc.xml · derivative · entry 2 Andrews Julie · CIK 0001550508 · VP, Finance & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,651 Underlying: Ordinary Shares · 10,651 shares Expires 2028-07-24 F3 · derivative.exercise_date: This option vests with respect to 25% of the shares on July 24, 2019 and with respect to the remaining 75% of such shares over the three-year period thereafter in 36 as nearly equal as possible monthly installments. Read SEC document |
| July 24, 2018 Filed Jul 26, 2018 16:06 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | GrantOrdinary Shares, par value EUR 0.03 per share | 3,970 | $0.00 | $0.00 |
DisclosureSEC source: 0001235802-18-000099 · primary_doc.xml · nonDerivative · entry 1 Andrews Julie · CIK 0001550508 · VP, Finance & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,271 F1 · shares: These ordinary shares will be issued over time upon vesting pursuant to a restricted stock unit granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan. F2 · balance_after: Includes 5,205 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2010 Incentive Plan and 7,568 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan. Read SEC document |
| June 04, 2018 Filed Jun 6, 2018 16:01 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | SaleOrdinary Shares, par value EUR 0.03 per share | 1,466 | $24.62 | $36,092.92 |
DisclosureSEC source: 0001235802-18-000070 · primary_doc.xml · nonDerivative · entry 1 Andrews Julie · CIK 0001550508 · VP Finance & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,301 F1 · kind: These shares were sold under a pre-arranged sales instruction pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, to cover the estimated tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.48 to $24.84, inclusive. The reporting person undertakes to provide to Wright Medical Group N.V., any security holder of Wright Medical Group N.V., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F3 · balance_after: Includes 5,205 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2010 Incentive Plan and 3,598 ordinary shares that will be issued over time upon vesting pursuant to a restricted stock unit granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.